Αρχική World News Triple Blockade Demonstrates High Response Rates in Metastatic Melanoma

Triple Blockade Demonstrates High Response Rates in Metastatic Melanoma

Patients with unresectable and/or metastatic melanoma achieved high rates of durable response following treatment with a triplet regimen of PD-1 inhibitor, spartalizumab in combination with the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib. Findings from the efficacy, safety, and biomarker analysis of parts 1 and 2 of the randomised, placebo-controlled phase III COMBI-i trial (NCT02967692) were reported in the Nature Medicine on 5 October 2020.

Reinhard Dummer, Professor at the University of Zurich and Vice-Chairman of the Department of Dermatology in the University Hospital of Zürich, Switzerland and colleagues conducted this analysis of COMBI-i data.

All 36 patients with previously untreated BRAF V600-mutant unresectable or metastatic melanoma were treated with 400 mg of spartalizumab every 4 weeks plus 150 mg of dabrafenib twice daily and 2 mg of trametinib once daily. Part 2 of this trial was a biomarker analysis that characterised changes in PD-L1 levels and CD8+ cells following treatment as the primary endpoint, and investigated additional biomarkers; efficacy per RECIST and safety were key secondary endpoints.

The triplet regimen led to durable responses

With median follow-up of 24.3 months, the spartalizumab, dabrafenib, and trametinib regimen provided a 78% confirmed objective response rate (ORR; 95% confidence interval [CI] 61–90) consisting of 44% complete response (CR) and 33% partial response (PR). In addition, 17% of patients showed stable disease, just 3% of patients experienced progressive disease (PD), and 3% had unknown outcome, leading to a 95% disease control rate (DCR; CR+PR+SD). In responding patients, the median duration of response (DoR) was not estimable (NE; 95% CI 17 months-NE). The 12- and 24-month rates were 80% and 53%, respectively.

Regarding survival, the median progression-free survival (PFS) was 23 months (95% CI 12-NE), with 12- and 24- month rates of 67% and 41%, respectively. Median overall survival (OS) was NE (95% CI NE-NE) and the respective OS rates at 12- and 24-months were 86% and 74%.

A subgroup of 15 patients with an LDH level ≥1× the upper limit of normal at baseline demonstrated a confirmed ORR of 67%, comprising 27% CR, 40% PR, 20% SD, 7% PD, and 7% unknown. The DCR was 87%, and median DoR was NE (95% CI 4-NE), with 12- and 21-month rates of 65% and 52%, respectively. In this cohort, median PFS was 11 (95% CI 5–19) months, and the estimated 24-month PFS rate was 27%. Median OS was NE with an estimated 24-month OS rate of 53% (95% CI 25–74%).

The patients had a median exposure to the regimen of 13.4 (range, 2.5–29.4) months. All of the patients had at least one adverse event (AE), with 81% experiencing at least one grade ≥3 AE. Treatment-related AEs (TRAEs) were observed in all patients; of these 72% were grade ≥3 and included pyrexia (17%), increased lipase (11%), and neutropenia (11%).

All patients had temporary dose modifications due to AEs; of these, most were reversible with the exception of 17% of patients who permanently discontinued all 3 study drugs.

Complete response associated with low baseline ctDNA levels

The biomarker analysis included RNA sequencing (RNA-seq) and target DNA sequencing of tissue samples from patients with >12 months of follow-up. This analysis showed an association between early PFS events and low tumour mutational burden (TMB)/T cell–inflamed gene expression signature (GES) levels, high levels of specific immunosuppressive TME signatures, and elevated baseline levels of circulating tumour DNA.

An evaluation of biomarker profiles in samples from patients achieving CR compared with the profiles of all other patients revealed an association between CR and low or no detectable baseline ctDNA levels. CR did not associated with known markers for immunotherapy response such as TMB and T cell–inflamed GES but did associate with tumours having lower baseline levels of immunosuppressive TME signatures.  

Biomarker modulations following treatment were assessed by tissue immunohistochemistry, RNA-seq, and comparison of plasma IFN-γ levels between baseline and on-treatment samples. Unpaired comparisons among different time-points showed upregulation of PD-L1; at baseline, 68% of patients had a PD-L1-positive tumour, whereas 91% of patients with available PD-L1 results had a PD-L1-positive tumour after 2–3 weeks of treatment. Additionally, 25 of 27 (93%) patients had elevated plasma IFN-γ levels following 4 weeks of treatment. Furthermore, an increase in T cell–specific GESs was observed by RNA-seq when paired baseline and 2- to 3-week on-treatment biopsies were compared. Furthermore, cell cycle GESs were decreased from baseline levels to the time of biopsy taken at 2–3 weeks.

Conclusions

According to the authors, the 24-month OS rate of 74% observed with spartalizumab, dabrafenib, and trametinib compares favourably with OS rates from phase III trials of either dabrafenib plus trametinib or anti-PD-1 therapy.

They noted that it will be important to track the change in benefits over time with this regimen and pointed out that the ongoing randomised, placebo-controlled, phase III portion of COMBI-i will further clarify the potential of spartalizumab plus dabrafenib and trametinib in patients with BRAF V600-mutant metastatic melanoma.

Funding for COMBI-i was reported from Novartis.

Reference

Dummer  R, Lebbé C, Atkinson V, et al. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nature Medicine, 2020;26:1557–1563. DOI: https://doi.org/10.1038/s41591-020-1082-2.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Avapritinib Not Superior to Regorafenib in Terms of Median PFS in Third-Line or Later Treatment of Patients with Unresectable or Metastatic GIST

Findings from an open-label, randomised, multicentre phase III VOYAGER study indicate that avapritinib is not superior to regorafenib in terms of median progression-free survival...

Patients less likely to rate cancer care as ‘very good’ during pandemic

Almost a third of cancer patients have reported receiving worse care since COVID-19 began, according to a new survey commissioned by Cancer Research UK. Whilst...

How to Avoid Spreading Harmful Chemo Chemicals to Members of Your Household

Cancer is not contagious, and neither is chemotherapy. However, harmful chemotherapy drugs can sometimes still be present in the bodily fluids of a person...

Can’t Sleep? Tips for Coping with Insomnia

Insomnia* is common for cancer patients**, as well as for the general population. We frequently hear from our patients and their caregivers that sleeping through the night...

New Task Force Focuses on Quality of Life for AYAs with Cancer

August 4, 2021, by NCI Staff Adolescents and young adults are using mobile devices to document the impact of cancer and its treatment on their...

Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated NSCLC

Amivantamab demonstrated robust and durable responses in patients with epidermal growth factor receptor Exon 20 insertion (EGFR Exon20ins)-mutated non-small cell lung cancer (NSCLC) after progression on...